Avitinib 是一种不可逆的、突变体选择性的EGFR抑制剂，可有效抑制非小细胞肺癌中EGFR T790M耐药突变。阿比替尼也是一种新型BTK抑制剂。

Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of Ys, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.

1557267-42-1

C26H26FN7O2

487.539

艾维替尼;AC0010

DMSO:88 mg/mL(180.5 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years